Skip to main content

Advertisement

SpringerLink
Log in

Dose-dependent ultrastructural and morphometric alterations after erythropoietin treatment in rat femoral artery vasospasm model

  • Experimental research
  • Published:
Acta Neurochirurgica Aims and scope Submit manuscript

Abstract

Purpose

Cerebral vasospasm is the common cause of poor outcome after aneurysmal subarachnoid hemorrhage (aSAH). Although many agents are experimentally and clinicaly used to protect or recover from vasospasm, an effective neurotherapeutic drug is still missing. Erythropoietin (EPO) is recently a promising candidate. The aim of this study is to investigate the dose-dependent effects of recombinant human EPO (rhEPO) on arterial wall in a rat femoral artery vasospasm model.

Methods

Thirty two animals were divided into four groups: vasospasm without any treatment (group A), vasospasm +250 IU/kg rhEPO group (group B), vasospasm +500 IU/kg rhEPO group (group C), and control group (group D). Rat femoral artery vasospasm model was used. For groups B and C, 7 days of 250 IU/kg and 500 IU/kg intraperitoneal rhEPO in 0.3 ml saline were administered respectively; and for groups A and D, 0.3 ml saline were administered intraperitoneally without any treatment. After 7 days, histological and morphometric analyses were carried out.

Results

Vasospasm alone group demonstrated the highest vessel wall thicknesses, comparing to other groups (p < 0.001). While for groups B and C, vessel wall thickness values were significantly higher than the control group (p < 0.001), between these two groups, there was no significant difference achieved (p > 0.05).

Conclusion

In our study, there was no significant difference between the two rhEPO treatment groups, but rhEPO treatment was shown to be histologically and morphometrically effective in vasospasm. However, if dosage of EPO treatment is augmented, successful results may be achieved.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Akisu M, Tuzun S, Arslanoglu S, Yalaz M, Kultursay N (2001) Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Med Okayama 55:357–362

    CAS  PubMed  Google Scholar 

  2. Ayer RE, Zhang JH (2008) Oxidative stress in subarachnoid haemorrhage: significance in acute brain injury and vasospasm. Acta Neurochir Suppl 104:33–41

    Article  CAS  PubMed  Google Scholar 

  3. Banerjee D, Rodriguez M, Nag M, Adamson JW (2000) Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 57:1895–1904

    Article  CAS  PubMed  Google Scholar 

  4. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT (2004) Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104:2073–2080

    Article  CAS  PubMed  Google Scholar 

  5. Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643–651

    Article  CAS  PubMed  Google Scholar 

  6. Brines ML, Ghezzi P, Kenan S, Agnello D, de Laner Olle NC, Cerami C et al (2000) Erytropoetin crosses the blood brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97(10):526–531

    Google Scholar 

  7. Cheng G, Wei L, Zhi-Dan S, Shi-Guang Z, Xiang-Zhen L (2009) Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway. BMC Neurosci 21(10):7

    Article  Google Scholar 

  8. Coleman TR, Westenfelder C, Togel FE, Yang Y, Hu Z, Swenson L et al (2006) Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 103:5965–5970

    Article  CAS  PubMed  Google Scholar 

  9. Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J (2007) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev Jul 18(3):CD000277. Review

    Google Scholar 

  10. d’Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS (2007) Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 49:1142–1148

    Article  PubMed  Google Scholar 

  11. Grasso G, Buemi M, Corica F, Calapani G, Salpietro FM, Casuscelli T et al (2000) In vivo evidence that erythtropoetin has a neuro-protective effect during subarachnoid hemorrhage. Eur J Pharmacol 392:31–34

    Article  PubMed  Google Scholar 

  12. Ito H, Fukunaga M, Suzuki H, Miyakoda G, Ishikawa M, Yabuuchi Y, Taki W (2008) Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis 32:157–161

    Article  CAS  PubMed  Google Scholar 

  13. Kern M, Lam MM, Knuckey NW, Lind CR (2009) Statins may not protect against vasospasm in subarachnoid haemorrhage. J Clin Neurosci 16:527–530, Epub 2009

    Article  CAS  PubMed  Google Scholar 

  14. Kiriş T, Karasu A, Yavuz C, Erdem T, Unal F, Hepgül K, Baloğlu H (1999) Reversal of cerebral vasospasm by the nitric oxide donor SNAP in an experimental model of subarachnoid haemorrhage. Acta Neurochir (Wien) 141:1323–1328, discussion 1328–1329

    Article  Google Scholar 

  15. Kramer AH, Zygun DA, Bleck TP, Dumont AS, Kassell NF, Nathan B (2009) Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 10:157–165

    Article  CAS  PubMed  Google Scholar 

  16. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al (2005) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239–242

    Article  Google Scholar 

  17. Mayberg MR, Okada T, Bark DH (1990) Morphologic changes in cerebral arteries after subarachnoid hemorrhage. Neurosurg Clin N Am 1:417–432

    CAS  PubMed  Google Scholar 

  18. Mayberg MR, Okada T, Bark DH (1990) The significance of morphological changes in cerebral arteries after subarachnoid hemorrhage. J Neurosurg 72:626–633

    Article  CAS  PubMed  Google Scholar 

  19. Mori K, Miyazaki M, Hara Y, Aiko Y, Yamamoto T, Nakao Y (2009) Novel vasodilatory effect of intracisternal injection of magnesium sulfate solution on spastic cerebral arteries in the canine two-hemorrhage model of subarachnoid hemorrhage. J Neurosurg 110:73–78

    Article  PubMed  Google Scholar 

  20. Mori K, Miyazaki M, Iwata J, Yamamoto T, Nakao Y (2008) Intracisternal infusion of magnesium sulfate solution improved reduced cerebral blood flow induced by experimental subarachnoid hemorrhage in the rat. Neurosurg Rev 31:197–203, discussion 203

    Article  PubMed  Google Scholar 

  21. Murphy AM, Xenocostas A, Pakkiri P, Lee TY (2008) Hemodynamic effects of recombinanthuman erythropoietin on the central nervous system after subarachnoid hemorrhage: reduction of microcirculatory impairment and functional deficits in a rabbit model. J Neurosurg 109:1155–1164

    Article  PubMed  Google Scholar 

  22. Okada T, Harada T, Bark DH, Mayberg MR (1990) A rat femoral artery model for vasospasm. Neurosurgery 27:349–356

    Article  CAS  PubMed  Google Scholar 

  23. Pluta RM (2008) Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Acta Neurochir Suppl 104:139–147, Review

    Article  CAS  PubMed  Google Scholar 

  24. Rinkel GJ, Feigin VL, Algra A, Vermeulen M, van Gijn J (2002) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 4:CD000277

  25. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C et al (2000) Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 97:609–613

    Article  Google Scholar 

  26. Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635–4640

    Article  CAS  PubMed  Google Scholar 

  27. Santhanam AV, Katusic ZS (2006) Erythropoietin and cerebral vascular protection:role of nitric oxide. Acta Pharmacol Sin 27:1389–1394, Review

    Article  CAS  PubMed  Google Scholar 

  28. Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS (2005) Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 36:2731–2737

    Article  CAS  PubMed  Google Scholar 

  29. Schubert GA, Schilling L, Thomè C (2008) Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. J Neurosurg 109:1134–1140

    Article  CAS  PubMed  Google Scholar 

  30. Springborg JB, Møller C, Gideon P, Jørgensen OS, Juhler M, Olsen NV (2007) Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 149:1089–1101, discussion 1101

    Article  CAS  Google Scholar 

  31. Springborg JB, Sonne B, Frederiksen HJ, Foldager N, Poulsgaard L, Klausen T, Jorgensen OS, Olsen NV (2003) Erythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brain. Brain Res 984:143–148

    Article  CAS  PubMed  Google Scholar 

  32. Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Caputi AP (1999) Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 127:482–488

    Article  CAS  PubMed  Google Scholar 

  33. Sugawara T, Ayer R, Zhang JH (2008) Role of statins in cerebral vasospasm. Acta Neurochir Suppl 104:287–290

    Article  CAS  PubMed  Google Scholar 

  34. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K (2008) Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 48:241–247, discussion 247–248

    Article  Google Scholar 

  35. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ (2009) Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. J Neurosurg 111:171–180

    Article  CAS  PubMed  Google Scholar 

  36. Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L (2007) Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 27:552–563

    Article  CAS  PubMed  Google Scholar 

  37. Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT (2006) Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 5:71–78

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest

None

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Haseki Training and Research Hospital, Istanbul, Turkey

    Ismail Ulusal, Rabia Tari, Gulsah Ozturk, Ezgi Aycicek & Turgay Bilge

  2. Department of Histology and Embryology, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

    Fadime Aktar

  3. Department of Neurosurgery, Istanbul Training and Research Hospital, Istanbul, Turkey

    Kadir Kotil

  4. Department of Neurosurgery, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey

    Talat Kırış

  5. Adnan Adıvar cad. Haseki Eğitim ve Araştırma Hastanesi Beyin, Cerrahisi Kliniği Fatih, Istanbul, Turkey

    Rabia Tari

Authors
  1. Ismail Ulusal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rabia Tari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gulsah Ozturk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ezgi Aycicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fadime Aktar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kadir Kotil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Turgay Bilge
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Talat Kırış
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rabia Tari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ulusal, I., Tari, R., Ozturk, G. et al. Dose-dependent ultrastructural and morphometric alterations after erythropoietin treatment in rat femoral artery vasospasm model. Acta Neurochir 152, 2161–2166 (2010). https://doi.org/10.1007/s00701-010-0775-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00701-010-0775-6

Keywords

Search

Navigation